Bavarian Nordic (BAVA)

Business description

Bavarian Nordic is a Danish biotech focused on developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Its lead products are Prostvac (prostate cancer) and Imvamune (smallpox).

Share price chart

Share chart

Stock data

Market cap.DKK8844.2m
Last closeDKK318.00
High / Low (52 weeks)DKK387.5 / DKK107.5
Stock market listingOMX
Forecast net cash (DKKm)1117
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual(4.4)(10.8)149.4
Relative *(1.7)(10)98.8

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Abzena Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
Agennix Alchemia
Alexza Pharmaceuticals Algeta
Alimera Sciences ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma Astex Pharmaceuticals
Athersys Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Balda
Basilea Pharmaceutica Bellus Health
Benitec Biopharma BioCryst Pharmaceuticals
BioInvent BioLight Life Sciences Inv
BioLineRx Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio BrainStorm Cell Therapeutics
BTG Can-Fite BioPharma
Capstone Therapeutics Carmat
Celldex Therapeutics Cellectis
Celyad Cerulean
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel Consort Medical
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
EKF Diagnostics Emergent BioSolutions
Endocyte Epigenomics
Epistem Holdings Erytech Pharma
Esperion Therapeutics Evolva
Evotec Exact Sciences
Exelixis Formycon
Forward Pharma Futura Medical
Galapagos Galmed Pharmaceuticals
Genfit Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunodiagnostic Systems Holdings ImmuPharma
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Invion Ion Beam Applications
Ipsogen Iridex
Ironwood Pharmaceuticals Islet Sciences
Ixico KaloBios Pharmaceuticals
Karolinska Development Keryx Biopharmaceuticals
LCA-Vision LeMaitre Vascular
Lifeline Scientific Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene Midatech
Molecular Partners MolMed
Mologen AG Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Nektar Therapeutics
NeoStem Neovacs
Newron Pharmaceuticals Nexstim
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novogen
NPS Pharmaceuticals Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Pixium Vision
Prescient Therapeutics Prima BioMed
Probiodrug ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Quantum Pharmaceuticals
Regeneus Relmada Therapeutics
ReNeuron Group Resverlogix
REVA Medical Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals TearLab Corp
Tekmira TESARO
Theraclion Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Regenix Group
Tissue Therapies Tonix Pharmaceuticals
Topotarget Transgene
Trillium Therapeutics Trimel Pharmaceuticals
UCB UDG Healthcare
uniQure NV Universal Biosensors
Vectura Verastem
Verisante Technology Vernalis
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Wilex
Xencor Zafgen
Zealand Pharma Zeltia
Ziopharm Oncology

Company news

Bavarian Nordic A/S Issues New Shares in Connection with Exercise of Warrants

Mon, 18 May 2015 09:56:15 GMT

Bavarian Nordic A/S - Report on the Results of the Annual General Meeting ...

Thu, 23 Apr 2015 19:13:12 GMT

Johnson & Johnson, Bavarian Nordic ink $187M deal for Ebola virus vaccine

Thu, 23 Oct 2014 00:33:45 GMT

Total number of voting rights and share capital in Bavarian Nordic A/S

Sun, 31 May 2015 15:00:00 GMT

BRIEF-AJ Aamund A/S sells all shares in Bavarian Nordic A/S

Tue, 27 Jan 2015 07:11:50 GMT

Y/E Dec Revenue (DKKm) EBITDA (DKKm) PBT (DKKm) EPS (øre) P/E (x) P/CF (x)
2013A 1213.0 181.0 154.0 38.8 8.2 0.5
2014A 1217.0 62.0 110.0 27.3 11.6 0.2
2015E 1188.0 171.0 121.0 39.6 8.0 0.4
2016E 1357.0 285.0 239.0 81.4 3.9 0.4

Last updated on 24/06/2015

Investment summary

Successful partnerships and collaborations, most recently with J&J for Ebola and BMS for Prostvac, have provided Bavarian Nordic with sufficient resources to focus on expanding and developing its earlier-stage pipeline. This includes CV-301, now focused on lung cancer, and the start of Phase I development of MVA-BN RSV in H115, which could be a significant new opportunity. The BMS deal will also allow Prostvac's potential to be maximised through exploring combinations with various other cancer immunotherapy products in development at BMS. Furthermore, recent Imvamune data, in particular with the freeze-dried formulation, should support additional US government orders to maintain the current strategic national stockpile. The manufacturing process is being up-scaled in readiness for potential new orders from 2016.

Last updated on 29/06/2015

Industry outlook

Bavarian Nordic has expertise in both vaccines (with two technology platforms) and manufacturing (with a multipurpose, approved facility). The pipeline includes two Phase III assets (Prostvac and Imvamune) and is largely focused on cancer immunotherapy (Prostvac and CV-301) and infectious diseases (Imvamune/smallpox, RSV and Ebola).

Last updated on 29/06/2015

Key management

Gerard van Odijk, Chairman
Paul Chaplin, CEO
Ole Larsen, CFO
Rolf Sass, IR

Company address

Hejreskovvej 10A
DK-3490 Kvistgaard
Denmark
View website